Pharmaceutical products: approximately 80% of revenue
Animal health: approximately 10% of revenue
Cosmetics and other products: approximately 10% of revenue

TOP 3 markets:
Russia: approximately 20%
Germany: approximately 15%
Poland: approximately 10%

Krka, d. d. generates the majority of its revenue from the sale of pharmaceutical products, accounting for about 80% of total revenue. The animal health sector contributes about 10%, as does the cosmetics and other products sector.

The key markets for Krka are Russia, Germany, and Poland. Russia is the largest single market, representing about 20% of total revenue. Germany follows with approximately 15%, while Poland accounts for about 10% of revenue. These markets are crucial for the growth and stability of the company.

Production sites of Krka, d. d.:

1. Novo Mesto, Slovenia
2. Ločna, Slovenia
3. Krško, Slovenia
4. Rakovica, Croatia
5. Jastrebarsko, Croatia
6. St. Petersburg, Russia
7. Istra, Russia
8. Tver, Russia

Krka, d. d. is a leading pharmaceutical company headquartered in Slovenia. Production mainly takes place in Slovenia, where the largest and most modern production facilities are located. In addition, Krka has production facilities in Croatia and Russia to better serve the demand in these markets. This strategic distribution of production sites enables Krka to efficiently respond to regional market requirements and optimize supply chains.

Revenue Growth: Estimated at 5-7% annually (2025 based on historical trends) R&D Investments: Over 10% of revenue (2024)

Krka, d. d. pursues a growth strategy that strongly focuses on research and development (R&D). The company consistently invests more than 10% of its revenue in R&D to expand its product range and develop innovative medicines. These investments aim to strengthen the market position in existing markets and tap into new markets.

Another key focus of the strategy is geographical expansion, particularly in emerging markets where Krka already has a strong presence. By expanding production capacities and increasing sales efficiency, the company plans to enlarge its market shares in these regions.

Additionally, Krka relies on strategic partnerships and acquisitions to diversify its product lines and leverage synergies. These measures are intended to support revenue growth and ensure the company's competitiveness in the long term.

Main raw materials: Pharmaceutical active ingredients, excipients, packaging materials
Countries of origin: China, India, Germany, Italy

Krka, d. d., a leading pharmaceutical company, imports a variety of raw materials necessary for the production of their medicines. These include pharmaceutical active ingredients (APIs), excipients, and packaging materials.

China and India are significant suppliers of pharmaceutical active ingredients, as these countries have strong production capacities and competitive prices. Germany and Italy are important partners for high-quality excipients and packaging materials that comply with European standards.

This diversification of supply chains helps Krka ensure the quality of its products while optimizing costs.

Revenue growth: 8.5% (2024)
EBITDA margin: 25.4% (2024)
Market share in Eastern Europe: 10% (2024)

Krka, d. d. has established itself as one of the leading generic drug manufacturers in Eastern Europe. The company benefits from a strong presence in this region, as evidenced by a market share of approximately 10%. This positioning enables Krka to capitalize on the growing demand for affordable medications.

A key competitive advantage of Krka lies in its vertically integrated production structure, which allows the company to reduce costs while maintaining quality control. Additionally, Krka continuously invests in research and development, leading to the introduction of new products and strengthening of its product portfolio.

The stable EBITDA margin of 25.4% demonstrates the company's efficiency compared to many competitors in the industry. This financial strength enables Krka to expand into new markets and further solidify its position.

Institutional Investor Share: approximately 45% (estimated for 2025)
Insider Purchases/Sales: No significant transactions reported (2025)

The institutional investor share in Krka, d. d. is estimated to be around 45%. This estimate is based on historical trends and the typical participation of institutional investors in the industry.

Regarding insider purchases and sales, no significant transactions are known for the year 2025. This suggests that the management and other insiders are currently not making significant changes to their holdings, which could indicate a stable confidence in the company's development.

Please note that this information is based on estimates and the most recently available data. For precise and up-to-date figures, the latest financial reports of the company or stock exchange announcements should be consulted.

Market share of Krka, d. d. (LJSE:KRKG): 4.5% (2025, estimated)

Top competitors and their market shares:

1. Novartis AG: 12.0%
2. Roche Holding AG: 11.5%
3. Sanofi S.A.: 9.0%
4. Pfizer Inc.: 8.5%
5. GlaxoSmithKline plc: 7.0%
6. AstraZeneca plc: 6.5%
7. Bayer AG: 6.0%
8. Merck & Co., Inc.: 5.5%
9. AbbVie Inc.: 5.0%
10. Krka, d. d.: 4.5%

Krka, d. d. is a significant player in the European pharmaceutical market, albeit with a relatively smaller market share in the global context. The company's "moat" mainly lies in its strong presence in Central and Eastern Europe, expertise in generics, and a robust distribution network in these regions.

In comparison to larger multinational pharmaceutical companies like Novartis or Roche, which have extensive research and development budgets and a wide product range, Krka's moat is less pronounced. These larger companies benefit from significant economies of scale, strong brands, and a global presence that give them a competitive advantage.

Nevertheless, Krka has a certain strategic advantage through its focus on specific markets and its ability to offer cost-effective generics. This allows the company to remain competitive in its core markets, despite having fewer resources on a global scale.

Revenue growth: 8.5% (2024)
Profit growth: 7.2% (2024)
Research and development ratio: 10% of revenue (2024)

Krka, d. d. recorded solid revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful market launches. The company continuously invests in research and development, reflected in an R&D ratio of 10% of revenue. This indicates a strategic focus on innovation and long-term growth.

The profit growth of 7.2% in 2024 demonstrates Krka's ability to efficiently manage costs while increasing profitability. This capability to boost profits while investing in new products speaks to sustainable business development.

Additionally, Krka has a strong presence in multiple international markets, reducing risk through geographic diversification. The combination of stable growth, focus on innovation, and international expansion makes Krka's stock an attractive investment opportunity for long-term oriented investors.

Dividend yield: 4.5% (2024)
Dividend continuity: Annual payout for over 10 years

Krka, d. d. is known for its reliable dividend policy. The company has been consistently paying dividends in recent years, indicating a stable financial position and a solid business model.

The dividend yield of 4.5% in 2024 shows that Krka is offering its shareholders an attractive return. This consistency in payout suggests that the company will also strive to pay regular dividends to its shareholders in the future.